The 4 Root Dysfunctions Behind PMOS (and the Peptides That Target Each)

The rename from PCOS to PMOS did something critical that decades of clinical guidelines failed to do: it named the disease for what it actually is. A polyendocrine, metabolic condition that also affects the ovaries.

But what does that mean in practice? If PMOS is not about cysts, what is it about? The answer is four interconnected dysfunctions, each feeding the others in a self-reinforcing cycle. Understanding these four roots is not academic. It is the difference between treating symptoms and addressing causes.

Dysfunction 1: Insulin Resistance

Insulin resistance is documented in approximately 75 percent of women with PMOS, making it the most prevalent root dysfunction regardless of body weight. It is not a consequence of PMOS. It is a driver.

In insulin resistance, cells become less responsive to insulin signaling, forcing the pancreas to produce more insulin to maintain blood sugar control. This excess insulin, called hyperinsulinemia, has downstream effects throughout the endocrine system that are specific to PMOS.

Elevated insulin directly stimulates ovarian theca cells to produce more androgens. It simultaneously suppresses sex hormone-binding globulin (SHBG) production in the liver, which means more free testosterone circulates in the blood. And it disrupts the hypothalamic signals that regulate the menstrual cycle, contributing to anovulation.

The Peptide Match: GLP-1 Receptor Agonists

Semaglutide and tirzepatide reduce insulin resistance through multiple mechanisms beyond weight loss. They improve pancreatic beta-cell function, slow gastric emptying, and reduce hepatic glucose production. In women with PMOS, studies show that GLP-1 RAs are superior to metformin in improving insulin sensitivity and produce measurable reductions in testosterone, free androgen index, and hirsutism scores.

Dysfunction 2: Androgen Excess

Hyperandrogenism is the hormonal hallmark of PMOS. It manifests as acne, excess facial and body hair (hirsutism), scalp hair thinning, and oily skin. But the visible symptoms are downstream effects. The real problem is upstream: disrupted androgen production in the ovaries and adrenal glands.

In a healthy reproductive cycle, ovarian theca cells produce androgens in controlled amounts, which granulosa cells then convert to estrogen through aromatization. In PMOS, this balance is disrupted. Excess LH stimulation drives theca cells to overproduce androgens. Insulin amplifies this effect. And insufficient FSH means granulosa cells cannot convert the excess androgens to estrogen efficiently.

The result is a hormonal environment dominated by androgens. Follicles begin to mature but stall before ovulation. They accumulate in the ovary as small antral follicles, which on ultrasound can appear as the “cysts” that gave the old condition its misleading name.

The Peptide Match: Kisspeptin-10

Kisspeptin is a master regulator of the hypothalamic-pituitary-gonadal axis. Research suggests that kisspeptin-10 can help normalize the LH pulse pattern in women with PMOS, potentially reducing the LH-driven androgen overproduction. Additionally, a 2026 study in PLOS ONE demonstrated that kisspeptin improves local ovarian insulin resistance through the PI3K/AKT/GLUT4 signaling pathway, suggesting it may address both the androgen excess and the insulin resistance simultaneously.

Dysfunction 3: LH/FSH Dysregulation

In a normal menstrual cycle, the pituitary gland releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a carefully timed pattern. The LH:FSH ratio is typically close to 1:1 in the early follicular phase, with a dramatic LH surge triggering ovulation mid-cycle.

In PMOS, this ratio is often inverted, sometimes reaching 2:1 or 3:1. LH is chronically elevated while FSH is relatively suppressed. The elevated LH continuously stimulates androgen production without the mid-cycle surge needed for ovulation. Meanwhile, suppressed FSH means follicles do not receive the signal to fully mature.

This neuroendocrine disruption originates in the hypothalamus and is mediated by GnRH (gonadotropin-releasing hormone) pulse frequency. In PMOS, GnRH pulses are faster than normal, which preferentially stimulates LH over FSH secretion.

The Peptide Match: Kisspeptin (Upstream Regulation)

Kisspeptin neurons sit upstream of GnRH neurons and regulate their firing pattern. Clinical research from Imperial College London has shown that exogenous kisspeptin administration can stimulate appropriate gonadotropin release in women with PMOS, potentially helping to reset the disordered LH/FSH balance. Unlike clomiphene, which works by blocking estrogen receptors, kisspeptin works through the natural regulatory pathway, which may reduce the risk of ovarian hyperstimulation.

Dysfunction 4: Chronic Inflammation

Low-grade chronic inflammation is the fourth root dysfunction, and it is the one most frequently overlooked in clinical practice. Women with PMOS show elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and other inflammatory markers independent of body weight.

This inflammation is not caused by infection or injury. It appears to originate from multiple sources: visceral adipose tissue producing inflammatory cytokines, gut dysbiosis with increased intestinal permeability, and the metabolic stress of chronic insulin resistance itself.

Inflammation worsens every other dysfunction. It impairs insulin receptor signaling, amplifying insulin resistance. It stimulates adrenal androgen production. It disrupts ovarian follicular development. And it increases cardiovascular risk, which is already elevated in PMOS.

The Peptide Match: BPC-157 and KPV

BPC-157 has demonstrated anti-inflammatory and cytoprotective properties in numerous preclinical studies, particularly for gut-related inflammation. Given the emerging evidence linking gut dysbiosis to PMOS, BPC-157's gut-healing properties are especially relevant. KPV, a tripeptide derived from alpha-MSH, has shown potent anti-inflammatory activity in models of inflammatory bowel conditions and may help address the chronic inflammatory component of PMOS.

The Vicious Cycle

These four dysfunctions do not exist in isolation. They create a self-reinforcing loop that is the fundamental reason PMOS is so difficult to treat with single-target therapies.

Insulin resistance drives androgen excess. Androgen excess promotes visceral fat accumulation, which worsens insulin resistance. Both generate inflammatory signals. Inflammation impairs insulin signaling and disrupts GnRH pulsatility. Disrupted GnRH elevates LH, which increases androgen production. And the cycle continues.

This is why the rename matters therapeutically. A condition named for ovarian cysts invited single-target treatment: suppress the cysts, regulate the period. A condition named for its polyendocrine metabolic nature invites multi-target approaches that address the full cycle.

Mapping Peptides to Each Dysfunction

The peptide research landscape for PMOS maps remarkably well to the four-dysfunction model:

Insulin Resistance: GLP-1 receptor agonists (semaglutide, tirzepatide) have the strongest evidence, with multiple randomized trials showing superiority to metformin in this population.

Androgen Excess: Kisspeptin-10 may help normalize the hormonal environment by acting on the upstream regulatory system. GLP-1 RAs also reduce androgens indirectly by improving insulin sensitivity.

LH/FSH Dysregulation: Kisspeptin targets the hypothalamic regulation of GnRH, potentially resetting the disordered pulse frequency. This is a fundamentally different mechanism from current treatments.

Chronic Inflammation: BPC-157 and KPV target inflammatory pathways. BPC-157 has particular relevance for gut-mediated inflammation, which is increasingly implicated in PMOS pathophysiology.